Early and widespread injury of astrocytes in the absence of demyelination in acute haemorrhagic leukoencephalitis
© Robinson et al.; licensee BioMed Central Ltd. 2014
Received: 30 April 2014
Accepted: 2 May 2014
Published: 8 May 2014
Acute hemorrhagic leukoencephalitis (AHL) is a fulminant demyelinating disease of unknown etiology. Most cases are fatal within one week from onset. AHL pathology varies with the acuteness of disease. Hemorrhages, vessel fibrinoid necrosis, perivascular fibrin exudation, edema and neutrophilic inflammation are early features, while perivascular demyelination, microglial foci and myelin-laden macrophages appear later. Reactive astrocytosis is not present in early hemorrhagic non-demyelinated lesions, but is seen in older lesions. This case report presents the pathology of an AHL case with fulminant course and fatal outcome within 48 hours from presentation. Severe hemorrhages, edema and neutrophilic inflammation in the absence of circumscribed perivascular demyelination affected the temporal neocortex and white matter, hippocampus, cerebellar cortex and white matter, optic chiasm, mammillary bodies, brainstem, cranial nerve roots and leptomeninges. Perivascular end-feet and parenchymal processes of astrocytes exhibited impressive swelling in haemorrhagic but non-demyelinated white matter regions. Astrocytes were dystrophic and displayed degenerating processes. Astrocytic swellings and remnants were immunoreactive for aquaporin-4, aquaporin-1 and glial fibrillary acidic protein. These morphological changes of astrocytes consistent with injury were also observed in haemorrhagic and normal appearing cortex. Our findings reinforce that perivascular demyelination is not present early in AHL. This is the first study that highlights the early and widespread astrocytic injury in the absence of demyelination in AHL, suggesting that, similarly to neuromyelitis optica and central pontine myelinolysis, demyelination in AHL is secondary to astrocyte injury.
Acute hemorrhagic leukoencephalitis (AHL), or Hurst’s disease, is a fulminant demyelinating disease of unknown etiology with fatal outcome within one week from onset due to severe cerebral edema and herniation[1, 2]. Histopathologically, AHL is characterized by the presence of perivascular haemorrhagic demyelinating lesions with prominent edema, axonal injury and predominantly neutrophilic parenchymal and meningeal inflammatory infiltrates[1, 2]. Based on the pathological similarities between acute disseminated encephalomyelitis (ADEM) and AHL, AHL is now considered a hyperacute variant of ADEM. In many cases, both AHL and ADEM occur within 2 to 4 weeks of a premonitory infection, most commonly a viral upper respiratory infection, although the prerequisite of an antecedent infection is neither specific nor sensitive for their diagnosis[1, 4, 5].
The pathological features of AHL differ between acute and late disease stages[6, 7]. Severe hemorrhages, fibrin impregnation of blood vessel walls and perivascular fibrin exudation, edema and predominantly neutrophilic inflammation are characteristic for the early AHL stages seen in patients with fulminant disease and fatal course within 2 days. Perivascular demyelination, perivascular microglial foci and myelin-laden macrophages appear later in the disease evolution as seen in patients with a longer disease course. Similarly, hypertrophic reactive astrocytes are not seen in early hemorrhagic non-demyelinated lesions, but may become apparent in older AHL lesions[7, 8]. Herein, we describe the pathology of a case of AHL with a fulminant and fatal course, and provide histopathological evidence that damage to astrocytes is an early event that precedes demyelination in AHL.
This study was approved by the University of Saskatchewan Biomedical Research Ethics Board (Bio-REB # 11–217). The Bio-REB issued a waiver of the requirement of consent for the examination of retrospective archival pathological material when patient or next of kin contact was not possible due to unavailable medical records and contact information (this is a 12 year old case). All samples were deidentified. Bio-REB considered the requirements of section 29 under the Health Information Protection Act (HIPA) and was satisfied that this study meets the privacy considerations outlined therein.
A 39 year old male patient presented to the ER department for new-onset seizures and severe headache preceded by three days of flu-like symptoms. A CT head was performed but revealed no abnormalities. The patient was prescribed sedatives and discharged home. The next day the patient became lethargic and slow to answer questions. Subsequently his level of consciousness deteriorated rapidly and he was found unconscious when Emergency Medical Services arrived. He was treated on site for narrow complex tachycardia (160/min) without any benefit and then transported to the ER. Neurological examination revealed deep coma (Glasgow Coma Scale 3/15) with pinpoint pupils. His general examination was remarkable for tachycardia (160/min), hypertension (214/116) and few respiratory crackles. He was intubated for airway protection. A CT scan revealed mild dilation of the ventricular temporal horns and poor grey – white matter differentiation. A chest X-ray was suggestive of pulmonary edema. An ECG revealed atrial flutter with 2:1 block that responded to amiodarone infusion. CBC showed 17.5X109 white blood cells/L (differential not available), normal haemoglobin and platelet counts. Drug screen and blood cultures were negative. CSF examination revealed bloody fluid, with increased protein (4.66 g/l) and 365 cells/μl with 75% lymphocytes and 25% polymorphonuclear leukocytes. CSF Gram stain and cultures were negative.
The patient was admitted to ICU where he reverted to narrow complex tachycardia and became hypotensive. He received DC shocks multiple times and the amiodarone bolus was repeated. The patient reverted to sinus rhythm, but remained hypotensive, and IV fluids and vasopressors were administered. He continued to deteriorate, went into a ventricular rhythm and was noted to have fixed dilated pupils. Despite cardiovascular support, he became asystolic and cardiopulmonary resuscitation proved unsuccessful. The patient was pronounced dead 3 hours after admission.
At autopsy, the brain was markedly swollen and weighed 1650 g. Gross examination revealed moderate cortical gyral flattening, and bilateral uncal and cerebellar tonsil herniation. Diffuse, spotty haemorrhages were noted in the temporal lobes, cerebellar hemispheres and brainstem. The large intracranial arteries at the base of the brain were normal in calibre and distribution, and showed no pathological changes. There was no evidence of aneurysm and no free blood in the cranial cavity. The spinal cord was unremarkable both grossly and microscopically.
Brain tissue was fixed in 10–15% formalin and embedded in paraffin. Sections, 5 μm thick, were stained with haematoxylin and eosin (HE) for morphological evaluation and Luxol-fast blue- haematoxylin and eosin (LFB/HE) to demonstrate myelin. Immunohistochemistry was performed using an avidin–biotin technique without modification. Antigen retrieval was performed as previously described. Tissues were exposed (16 hrs, at 4°C), to primary antibodies specific for: aquaporin-1 (AQP1; rabbit polyclonal 1:500; Santa Cruz, USA), aquaporin-4 (AQP4; affinity-purified rabbit polyclonal 1:250; Sigma-Aldrich, USA), glial fibrillary acidic protein (GFAP, mouse monoclonal 1:4000; Dako, Denmark), myelin proteolipid protein (PLP, rabbit polyclonal 1:500; Serotec, Oxford, USA), myelin oligodendrocyte glycoprotein (MOG, rabbit monoclonal 1:1000; Abcam, USA), myelin-associated glycoprotein (MAG, rabbit monoclonal 1:500; Sigma, USA), T lymphocytes (CD3, rat monoclonal 1:400; Serotec, USA), cytotoxic T lymphocytes (CD8, mouse monoclonal 1:50; Dako, Denmark), macrophages/microglial cells (CD68, mouse monoclonal 1:1000; Dako, Denmark), human immunoglobulin G (IgG, rabbit monoclonal 1:500; Epitomics, USA), herpes simplex virus 1 and 2 (HSV 1&2, rabbit polyclonal 10 mg/ml; Biocare Medical, USA) and cytomegalovirus (CMV, mouse monoclonal, 10 mg/ml; Biocare Medical, USA). Primary antibodies were omitted in control staining. In situ hybridization was performed using fluorescein-labeled oligonucleotide probes specific for Epstein-Barr Virus-Encoded RNA (EBER; Ventana Medical Systems, USA).
Apart from the presence of hemorrhages, edema with tissue vacoulation was the most prominent neuropathological feature observed both at gross examination and microscopically. Myelin was well preserved and perivascular demyelination not present. Myelin pallor was present in the inferior olive and cerebellar white matter and appeared to be due to spreading of the myelin sheaths because of edema and diffusion of an eosinophilic fibrin-like substance similar to the perivascular fibrin exudates conferring the white matter a sieve-like appearance (Figure 1k,l). Higher magnification of the myelinated fibers in these areas of myelin rarefaction revealed vacuolation and decompaction of myelin (Figure 1l, arrowheads). Rare apoptotic oligodendrocytes were present (Figure 1l, arrow).
Tissue stains for microorganisms, including HSV, EBV, CMV and fungi were negative. No viruses were isolated in the CSF collected at necropsy and the cryptococcal antigen test was negative.
Microscopic examination of the myocardium of the left ventricle and posterior wall of the right ventricle revealed the presence of polymorphonuclears, predominantly perivascularly. There was no evidence of necrosis, fibrosis or damage to the vessel wall, and no evidence of damage to the myocytes. Sections of the lungs revealed pulmonary edema, and there was acute congestion of the liver. Examination of other organs and tissues reveled no pathological changes.
While haemorrhagic perivascular demyelination is considered the histopathologic hallmark of AHL, previous studies have shown that the pathology of AHL varies with the acuteness of the disease[6, 7]. The predominance and severity of haemorrhages and edema, and the preponderance of neutrophils in inflammatory infiltrates we have found in this case coupled with the absence of frank perivascular demyelination, the absence of macrophages and the rarity of perivascular microglial infiltrates are acute histopathological features consistent with the short interval between onset and death in AHL, and similar to what is observed in AHL experimental models. In cases with a longer course, increasing proportions of macrophages and microglia are found in the inflammatory infiltrates, and perivascular demyelination may become obvious. Our findings corroborated with previously published studies reinforce the concept that disease stage influences AHL pathology: circumscribed perivascular demyelination is not present in fulminant cases with fatal outcome within 1 to 2 days from onset.
This is the first study that highlights the early and widespread injury of astrocytes in AHL. We show that both protoplasmic and fibrous astrocytes exhibit swelling of their end-feet and degeneration of their processes and cell bodies in the absence of demyelination and considerable oligodendrocyte injury, suggesting that astrocytes may be an early initial target in AHL and that demyelination is secondary. These findings may also explain the absence of reactive astrocytosis seen in this case, and other reported acute AHL cases. While we show that astrocytes are the first nervous cells affected in AHL, it is possible that primary vasculopathy with secondary tissue destruction-related neutrophil infiltration and vasogenic edema causes astrocytic injury.
However, we also found astrocytes with swollen processes and perivascular end-feet in cortical regions without hemorrhages, brain tissue inflammation or vascular changes. This reinforces the early astrocytic disturbance in AHL that may be independent of the presence of vascuolpathy, and raises interesting questions regarding the chronology of lesion development. Morphological changes of astrocytes similar to those described here have been reported in cytotoxic edema associated with hyponatremia, ischemia, brain trauma and hepatic encephalopathy[11–14]. Furthermore, imaging studies have shown that decreased apparent diffusion coefficient consistent with cytotoxic edema is present in AHL before the blood–brain barrier (BBB) is altered[15, 16]. All these findings show an important early role for cytotoxic edema in AHL and suggest that hypoxic, osmotic or toxic stress may drive the pathogenesis of this idiopathic disorder and/or render these central nervous system (CNS) regions more susceptible to BBB damage, free entry of blood toxins or autoantibodies, and development of lesions.
Meningeal inflammation is a constant pathological finding in ADEM and AHL[1, 6–8], and is the earliest histopathological feature observed in experimental allergic encephalomyelitis (EAE) and hyperacute EAE[10, 18], preceding the appearance of parenchymal inflammation and demyelination. Furthermore, we show that the upper cortical layers located in close proximity to the haemorrhagic and inflamed leptomeninges exhibit severe astrocytic fragmentation, while the further located deep cortical layers only show astrocyte swelling. It is therefore plausible that the cytotoxic swelling of astrocytes with or without breakdown of BBB may be caused by toxic products released by neutrophils and other inflammatory cells that have infiltrated the subarachnoid space, and suggest a potential beneficial role for neutrophil-depletion therapies in AHL[19, 20].
Both neuromyelitis optica (NMO) and central pontine myelinolysis (CPM) are primary astrocytopathies with secondary demyelination[21–23]. NMO is an autoimmune inflammatory astrocytopathy caused by anti-AQP4 complement-activating IgG autoantibodies[24, 25], while astrocytic injury in CPM is a consequence of the osmotic stress. Early lesions in both NMO and a subgroup of CPM patients are characterized by astrocytic damage, and loss of AQP4 in NMO and of both AQP4 and AQP1 in CPM[22, 23]. The BBB is altered in both NMO (required for the entry of the pathogenic autoantibodies into the CNS) and CPM (caused by endothelial shrinkage due to the rapid correction of chronic hypotonicity with a hyperosmolar solution). Loss of AQP4 in NMO is caused by its internalization by astrocytes or by complement-mediated destruction of astrocytes following binding of NMO-IgG to AQP4, while loss of AQP4 and AQP1 in CPM may represent a protective mechanism whereby astrocytes restrict water loss to prevent apoptosis. The disruption of the BBB coupled with the inability of astrocytes to either buffer or eliminate the excess water in NMO and CPM causes vasogenic edema and increased osmolarity of the CNS extracellular space and may trigger and/or exacerbate the intramyelinic edema, oligodendrocyte apoptosis and secondary demyelination. Early AHL lesions exhibit preservation of AQP4 and AQP1. Aquaporins represent the rate-limiting step for water flow from the vascular compartment into the CNS. Therefore, the preservation of AQP1 and AQP4 allows astrocytes to initially buffer the water that flows from the blood into the CNS through an intact BBB likely due to hypoosmolality or hypoxic energy failure that causes cytotoxic edema. However, in the presence of a persisting insult, the compensatory mechanisms ultimately fail and the swollen astrocytes die.
In conclusion, we present a case of AHL with rapid progression and fatal outcome within less than 48 hours from onset, whose neuropathologic picture is dominated by the widespread swelling and degeneration of astrocytes in the absence of demyelination, suggesting that, similarly to NMO and CPM, demyelination in AHL is secondary to astrocyte injury.
The authors thank Anita Givens, University Saskatchewan for her expert technical assistance and the Department of Pathology and Lab Medicine, Saskatoon Health Region for retrieval of tissue blocks, and performance of HSV and CMV IHC, and EBER ISH. R.C.A. and M.T. are Fellows in the Canadian Institutes of Health Research Training grant in Health Research Using Synchrotron Techniques (CIHR-THRUST). M.T. is supported by a College of Medicine Graduate Scholarship, University of Saskatchewan and a Saskatchewan Innovation and Opportunity Scholarship, Government of Saskatchewan. This work was supported by the Saskatchewan Health Research Foundation (to B.F.P.) and the Canada Research Chairs program (to B.F.P.).
- Hart MN, Earle KM: Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975, 38(6):585–591. 10.1136/jnnp.38.6.585View ArticlePubMedPubMed CentralGoogle Scholar
- Hurst EW: Acute haemorrhagic leucoencephalitis: a previously undefied entity. Med J Aust 1941, 28: 1–6.Google Scholar
- Russell DS: The nosological unity of acute haemorrhagic leucoencephalitis and acute disseminated encephalomyelitis. Brain 1955, 78(3):369–376.View ArticlePubMedGoogle Scholar
- Greenlee JE: Encephalitis and postinfectious encephalitis. Continuum 2012, 18(6):1271–1289. doi:10.1212/01.CON.0000423847.40147.06PubMedGoogle Scholar
- Young NP, Weinshenker BG, Lucchinetti CF: Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol 2008, 28(1):84–94. doi:10.1055/s-2007–1019130 10.1055/s-2007-1019130View ArticlePubMedGoogle Scholar
- Gosztoni G: Acute haemorrhagic leucoencephalitis. Report of three cases. Z Neurol 1973, 204(1):43–66.Google Scholar
- Lamarche JB, Behan PO, Segarra JM, Feldman RG: Recurrent acute necrotizing hemorrhagic encephalopathy. Acta Neuropathol 1972, 22(1):79–87. 10.1007/BF00687552View ArticlePubMedGoogle Scholar
- Adams RD, Cammermeyer J, Denny-Brown D: Acute necrotizing hemorrhagic encephalopathy. J Neuropathol Exp Neurol 1949, 8(1):1–29. 10.1097/00005072-194901000-00001View ArticlePubMedGoogle Scholar
- Vass K, Lassmann H, Wekerle H, Wisniewski HM: The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis. Acta Neuropathol 1986, 70(2):149–160. 10.1007/BF00691433View ArticlePubMedGoogle Scholar
- Levine S, Wenk EJ: A hyperacute form of allergic encephalomyelitis. Am J Pathol 1965, 47: 61–88.PubMedPubMed CentralGoogle Scholar
- Bosoi CR, Rose CF: Brain edema in acute liver failure and chronic liver disease: similarities and differences. Neurochem Int 2013, 62(4):446–457. doi:10.1016/j.neuint.2013.01.015 10.1016/j.neuint.2013.01.015View ArticlePubMedGoogle Scholar
- Kaur C, Sivakumar V, Zhang Y, Ling EA: Hypoxia-induced astrocytic reaction and increased vascular permeability in the rat cerebellum. Glia 2006, 54(8):826–839. doi:10.1002/glia.20420 10.1002/glia.20420View ArticlePubMedGoogle Scholar
- Pasantes-Morales H, Vazquez-Juarez E: Transporters and channels in cytotoxic astrocyte swelling. Neurochem Res 2012, 37(11):2379–2387. doi:10.1007/s11064–012–0777–2 10.1007/s11064-012-0777-2View ArticlePubMedGoogle Scholar
- Tani E, Evans JP: Electron microscope studies of cerebral swelling. 3. Alterations in the neuroglia and the blood vessels of the white matter. Acta Neuropathol 1965, 4(6):624–639. 10.1007/BF00691213View ArticlePubMedGoogle Scholar
- Lee HY, Chang KH, Kim JH, Na DG, Kwon BJ, Lee KW, Park SH: Serial MR imaging findings of acute hemorrhagic leukoencephalitis: a case report. AJNR Am J Neuroradiol 2005, 26(8):1996–1999.PubMedGoogle Scholar
- Mader I, Wolff M, Niemann G, Kuker W: Acute haemorrhagic encephalomyelitis (AHEM): MRI findings. Neuropediatrics 2004, 35(2):143–146. doi:10.1055/s-2004–817906View ArticlePubMedGoogle Scholar
- Levine S: Hyperacute, neutrophilic, and localized forms of experimental allergic encephalomyelitis: a review. Acta Neuropathol 1974, 28(3):179–189. 10.1007/BF00719023View ArticlePubMedGoogle Scholar
- Waksman BH, Adams RD: A histologic study of the early lesion in experimental allergic encephalomyelitis in the guinea pig and rabbit. Am J Pathol 1962, 41: 135–162.PubMedPubMed CentralGoogle Scholar
- Shiga Y, Onodera H, Kogure K, Yamasaki Y, Yashima Y, Syozuhara H, Sendo F: Neutrophil as a mediator of ischemic edema formation in the brain. Neurosci Lett 1991, 125(2):110–112. 10.1016/0304-3940(91)90003-CView ArticlePubMedGoogle Scholar
- Moxon-Emre I, Schlichter LC: Neutrophil depletion reduces blood–brain barrier breakdown, axon injury, and inflammation after intracerebral hemorrhage. J Neuropathol Exp Neurol 2011, 70(3):218–235. doi:10.1097/NEN.0b013e31820d94a5 10.1097/NEN.0b013e31820d94a5View ArticlePubMedGoogle Scholar
- Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T: The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014, 24(1):83–97. doi:10.1111/bpa.12099 10.1111/bpa.12099View ArticlePubMedPubMed CentralGoogle Scholar
- Popescu BF, Bunyan RF, Guo Y, Parisi JE, Lennon VA, Lucchinetti CF: Evidence of aquaporin involvement in human central pontine myelinolysis. Acta Neuropathol Commun 2013, 1(1):40. doi:10.1186/2051–5960–1-40 10.1186/2051-5960-1-40View ArticlePubMedPubMed CentralGoogle Scholar
- Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130(Pt 5):1194–1205. doi:10.1093/brain/awl371View ArticlePubMedGoogle Scholar
- Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202(4):473–477. doi:10.1084/jem.20050304 10.1084/jem.20050304View ArticlePubMedPubMed CentralGoogle Scholar
- Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA: NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers 2006, 22(4):197–206. 10.1155/2006/586306View ArticlePubMedPubMed CentralGoogle Scholar
- Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, Fallier-Becker P, Noell S, Lennon VA: Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012, 109(4):1245–1250. doi:10.1073/pnas.1109980108 10.1073/pnas.1109980108View ArticlePubMedGoogle Scholar
- Saadoun S, Papadopoulos MC: Aquaporin-4 in brain and spinal cord oedema. Neuroscience 2010, 168(4):1036–1046. doi:10.1016/j.neuroscience.2009.08.019 10.1016/j.neuroscience.2009.08.019View ArticlePubMedGoogle Scholar
- Szatkowski M, Attwell D: Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 1994, 17(9):359–365. 10.1016/0166-2236(94)90040-XView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.